Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD20-positive B cell (N/A)
- Target
- N/A
- Molecular classification
- B lymphocyte, Immune cell
01
Overview
CD20-positive B cells are a subset of B lymphocytes characterized by the expression of the CD20 surface antigen. They are involved in antibody production, antigen presentation, cytokine secretion, and immune regulation. Aberrant populations or functions of CD20-positive B cells are associated with autoimmune diseases and hematologic malignancies, making them therapeutic targets for monoclonal antibodies like rituximab.
02
Mechanism of action
Antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), direct apoptosis induction via anti-CD20 antibody binding.
03
Biological functions
Antibody productionAntigen presentationCytokine secretionImmune regulationMaintenance of resting state in mature B lymphocytesReceptor organization
04
Disease associations
AutoimmunityHematologic malignancy
05
Safety considerations
Infusion reactionsTumor lysis syndromeProgressive multifocal leukoencephalopathy (PML)Increased risk of infection
06
Interacting drugs
Rituximab
07
Biomarkers
CD20 expression level for patient selectionB cell counts for monitoring depletion therapy
Beyond the preview
Go deeper on CD20-positive B cell (N/A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD20-positive B cell (N/A).